STARIMAGIN.BO · BSE
STAR IMAGING AND PATH LAB LIMI
₹77.25
+0.99% (+₹0.76)
Prev. close
₹76.49
Volume
3,000
As of
BSE · may be slightly delayed · 13:51 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About STAR IMAGING AND PATH LAB LIMI
Star Imaging and Path Lab Limited operates as a diagnostic testing network and provides diagnostic imaging services and clinical laboratory tests in India. It offers diagnostic and radiology services, which includes X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, 4D and 5D ultrasounds, bone mineral densitometry, mammography, and orthopantomogram, surgical/anatomic pathology; pathology services, includes hematology, polymerase chain reaction, clinical pathology, histopathology, cytopathology, treadmill stress test, echocardiogram, microbiology, serology, cytology, immunology and bio chemistry, electrocardiogram, and immunology, holter monitoring, electroencephalogram, visual evoked potential, nerve conduction velocity, brainstem evoked response audiometry, electromyography, sleep study, pulmonary function test, fibro scan, and uroflowmetry; and other specialized testing services. It also provides Dexa scan, colour doppler, neurology, fetal echocardiography, dental imaging, CT Angiography, HMPV Rt-PCR test, Covid-19 test, and other tests, health packages as well as online reports access services. The company operates a tele-radiology hub. Star Imaging and Path Lab Limited was founded in 1978 and is based in New Delhi, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Pawan Gupta
Headquarters
New Delhi
Employees
236
Website
starimaging.inExchange
View on BSE ↗Key stats
Market cap
₹131.10 Cr
P/E ratio (TTM)
6.8
EPS (TTM)
₹11.05
Beta (1Y · daily vs NIFTY 50)
1.63
Shares float
47.00 L
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹58.68 Cr | ₹79.97 Cr | ₹83.50 Cr | ₹88.53 Cr | |
| EBITDA | — | ₹5.97 Cr | ₹23.55 Cr | ₹28.89 Cr | ₹34.16 Cr |
| — | ₹57.89 L | ₹12.42 Cr | ₹15.93 Cr | ₹19.28 Cr | |
| Diluted EPS | ₹3.61 | ₹0.33 | ₹7.13 | ₹9.14 | ₹11.05 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹61.23 Cr | ₹81.64 Cr | ₹98.16 Cr | ₹153.58 Cr | |
| ₹26.56 Cr | ₹30.64 Cr | ₹32.73 Cr | ₹20.67 Cr | |
| Stockholders' equity | ₹18.93 Cr | ₹31.35 Cr | ₹47.15 Cr | ₹116.10 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹5.27 Cr | ₹18.34 Cr | ₹-2.63 Cr | ₹23.34 Cr | |
| Investing cash flow | — | ₹-7.22 Cr | ₹-6.87 Cr | ₹-7.36 Cr | ₹-12.75 Cr |
| — | ₹-4.74 Cr | ₹1.89 Cr | ₹-37.31 L | ₹35.67 Cr | |
| Capital expenditure | — | ₹-7.30 Cr | ₹-8.45 Cr | ₹-4.22 Cr | ₹-10.25 Cr |
| End cash position | — | ₹2.35 Cr | ₹15.71 Cr | ₹5.35 Cr | ₹51.61 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| STAR IMAGING AND PATH LAB LIMI | ₹131.10 Cr | ₹74.75 | 6.8 | 1.13 | 16.6% | 0.18 | +6.0% | -44.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.